Senores Pharmaceuticals IPO Fully Subscribed On Day 1; Check GMP, Price Band And More
Senores Pharmaceuticals Ltd. opened for day one of subscription on Friday. The Rs 582.11-crore offering consists of a fresh issue of Rs 500 crore and an offer for sale of Rs 82.11 crore. It has been subscribed 1.78 times, as of 5:00 p.m. The retail portion has been fully subscribed to.
The price band for the IPO has been set between Rs 372 and Rs 391 per share. Promoters divesting shares in the OFS include Swapnil Jatinbhai Shah, Ashokkumar Vijaysinh Barot and Sangeeta Mukur Barot.
The grey market premium of Senores Pharmaceuticals was Rs 180 as of 3:28 p.m. on Friday, according to Chittorgarh's unit, InvestorGain. The estimated listing price based on the GMP is Rs 541 per share, implying a premium of 38.36%.
IPO Details
Issue opens: Dec. 20.
Issue closes: Dec. 24.
Issue price: Rs 372 to Rs 391 per share.
Offer for sale: Rs 82.11crore.
Fresh issue: Rs 500 crore.
Total issue size: Rs 582.11crore.
Lot size: Minimum 38 shares.
Use Of Proceeds
Investment in one of its subsidiaries, Havix Group, Inc. which does business under the name of Aavis Pharmaceuticals, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections at its Atlanta facility.
Re-payment or pre-payment, in full or in part, of certain borrowings.
Investment in company's subsidiary, Havix, for re-payment/pre-payment in full or in part, of certain borrowings availed by the subsidiary.
Funding the working capital requirements.
Investment in company's subsidiaries Senores Pharmaceuticals Inc. and Ratnatris Pharmaceutical Pvt. to fund their working capital requirements.
Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Subscription Status: Day 1Â
The IPO has been subscribed fully subscribed as of 5:00 p.m. on Friday.
Qualified institutional buyers: 0.01.
Non-institutional investors: 1.67 times.
Retail investors: 7.20 times.
Employee reserve: 1.88 times.
Business
Senores Pharmaceuticals is a global research driven pharmaceutical engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment, predominantly for the regulated markets across various therapeutic areas and dosage forms. Its regulated markets business is primarily focused on US, Canada, and the United Kingdom.
The company has adopted a strategy of identifying, developing and commercialising specialty and complex niche products in the mid-market range and as of March 31 they have received approvals for 19 abbreviated new drug applications.
It develops and manufacture generic pharmaceutical products across various therapeutic areas for emerging markets in the B2B segment, having a presence across 43 countries.
The company also operates a critical care injectables business, supplying critical care injectables to hospitals across India through distributors, and manufactures APIs for the domestic market and SAARC countries.
Senores Pharmaceuticals IPO GMP
The grey market premium of Senores Pharmaceuticals was Rs 180 as of 3:28 p.m. on Friday, according to Chittorgarh's unit InvestorGain. The estimated listing price based on the GMP is Rs 541 per share, implying a premium of 38.36%.
It is important to note that GMP or grey market price is not an official price quote for the stock and is based on speculation.
Watch The Video Here
Disclaimer: Investments in initial public offerings are subject to market risks. Please consult with financial advisors and read the red herring prospectus thoroughly before placing bids.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
